Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones Sustainability World Index

  Biogen Idec Becomes First U.S.-Based Biotech Named to Dow Jones
  Sustainability World Index

 – Company also Receives Top Carbon Disclosure Project Score for Transparency
                          in Global Biotech Sector –

Business Wire

WESTON, Mass. -- September 24, 2013

Biogen Idec (NASDAQ: BIIB) today announced that it has been added to the
prestigious Dow Jones Sustainability World Index (DJSI World) – becoming the
first and only U.S. based biotech sector firm to make the list. The company
was also named to the Dow Jones Sustainability Index (DJSI) North America for
the fourth consecutive year, one of only three biotech companies included.

Additionally, the Carbon Disclosure Project (CDP) released the results of its
Annual Investor Survey, awarding Biogen Idec the top Carbon Disclosure Score
for the biotech sector, and in the top 10 overall in the broader,
highly-competitive Healthcare category. The CDP is an international non-profit
organization focused on assessing the business risks and opportunities from
the environmental impact disclosure data of thousands of the world’s largest
companies. Biogen Idec significantly improved its score from the prior year,
demonstrating a high degree of transparency regarding its carbon footprint and
the company’s continued focus on being a more sustainable organization

“Biogen Idec has put great focus on citizenship and environmental
sustainability, directly incorporating them into our business activities and
making them a cultural imperative across our organization,” said George
Scangos, chief executive officer of Biogen Idec. “These accomplishments are a
testament to the commitment of our more than 6,000 employees worldwide to
exemplify high standards and create economic, social and environmental value
for our company and our stakeholders.”

Only 333 companies worldwide were named to the DJSI World in 2013, a report
that tracks the performance of the 2,500 largest companies in the S&P Global
Broad Market Index^SM. Biogen Idec’s overall DJSI score was significantly
above the industry average and represented an improvement over the year prior
-- even as the overall industry average dropped. The company scored in the
100^th percentile for its industry on 10 specific social, environmental and
economic dimensions including: corporate citizenship and philanthropy, talent
attraction and retention, occupational health and safety, and operational

Biogen Idec publishes an annual Corporate Citizenship Report based on
internationally recognized Global Reporting Initiative Guidelines. In its most
recent report, the company announced that it had achieved its goal of reducing
its overall environmental footprint by 15 percent in 2012, several years ahead
of schedule. The company also reported on its efforts to engage its employees
in improving the lives of patients and in the communities where it operates.

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and
delivers to patients worldwide innovative therapies for the treatment of
neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in
1978, Biogen Idec is the world's oldest independent biotechnology company.
Patients worldwide benefit from its leading multiple sclerosis therapies, and
the company generates more than $5 billion in annual revenues. For product
labeling, press releases and additional information about the company, please


Biogen Idec
Jason Glashow, +1 781-464-3260
Biogen Idec
Claudine Prowse, + 781-464-2442
Press spacebar to pause and continue. Press esc to stop.